[Lung-scintigraphy in the control of children with malignancies treated by radiochemotherapy (author's transl)].
Cytostatics- and radiation-induced alterations of the parenchyma of the lung were investigated in 30 children with malignomas before, during and after therapy by means of lung perfusion scintigraphy. Before the tumour-therapy (2 children) lung-scintigrams were regular. 16 children (Hodgkin- and non Hodgkin-lymphoma, acute lymphocytic leukemia with mediastinal tumour, intrathoracal neuroblastoma and Ewing-sarcoma) received epidiaphragmatical radiation and cytostatics. All 35 lung-scintigrams of these patients (1-60 months after beginning of therapy) were abnormal. Within 6 months after radiation obstructions to perfusion could be demonstrated in ray-treated parenchyma of the lung only. Subsequent to 6 months after radiation, during cytostatics, disturbances of perfusion were diffusely spreading in the lung parenchyma. 12 children (acute lymphocytic leukemia, Histiocytosis X and osteogenic sarcoma) received cytostatics only. All 18 lung-scintigrams of these patients (1-55 months after beginning of therapy) were pathological. After cessation of therapy (radiochemotherapy or chemotherapy only) scintigraphically improvement of perfusion occurred in the majority of patients. Obviously the diffusely spreading obstructions to perfusion represent alterations during the early phase of their development induced by chemotherapy.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging*; D008171:Lung Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000209:etiology; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011652:Pulmonary Circulation; D011832:Radiation Injuries / Q000000981:diagnostic imaging / Q000209:etiology; D011877:Radionuclide Imaging; D011878:Radiotherapy / Q000009:adverse effects*
D000970:Antineoplastic Agents
Lungenszintigraphie zur Uberwachung zytostatisch und radiologisch behandelter Kinder mit malignen Tumoren.